BioAge Labs (BIOA) Competitors $4.18 -0.10 (-2.34%) As of 07/7/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock BIOA vs. CDXC, DNTH, MENS, MGTX, UPB, XNCR, EOLS, KALV, IOVA, and ARVNShould you be buying BioAge Labs stock or one of its competitors? The main competitors of BioAge Labs include ChromaDex (CDXC), Dianthus Therapeutics (DNTH), Jyong Biotech (MENS), MeiraGTx (MGTX), Upstream Bio (UPB), Xencor (XNCR), Evolus (EOLS), KalVista Pharmaceuticals (KALV), Iovance Biotherapeutics (IOVA), and Arvinas (ARVN). These companies are all part of the "pharmaceutical products" industry. BioAge Labs vs. Its Competitors ChromaDex Dianthus Therapeutics Jyong Biotech MeiraGTx Upstream Bio Xencor Evolus KalVista Pharmaceuticals Iovance Biotherapeutics Arvinas BioAge Labs (NASDAQ:BIOA) and ChromaDex (NASDAQ:CDXC) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment. Does the media prefer BIOA or CDXC? In the previous week, BioAge Labs had 1 more articles in the media than ChromaDex. MarketBeat recorded 1 mentions for BioAge Labs and 0 mentions for ChromaDex. ChromaDex's average media sentiment score of 0.00 beat BioAge Labs' score of -0.17 indicating that ChromaDex is being referred to more favorably in the news media. Company Overall Sentiment BioAge Labs Neutral ChromaDex Neutral Is BIOA or CDXC more profitable? ChromaDex has a net margin of 1.62% compared to BioAge Labs' net margin of 0.00%. ChromaDex's return on equity of 4.85% beat BioAge Labs' return on equity.Company Net Margins Return on Equity Return on Assets BioAge LabsN/A N/A N/A ChromaDex 1.62%4.85%2.70% Do analysts rate BIOA or CDXC? ChromaDex has a consensus price target of $9.03, indicating a potential upside of 0.00%. Given ChromaDex's stronger consensus rating and higher possible upside, analysts plainly believe ChromaDex is more favorable than BioAge Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAge Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00ChromaDex 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, BIOA or CDXC? ChromaDex has higher revenue and earnings than BioAge Labs. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioAge LabsN/AN/A-$71.11MN/AN/AChromaDex$99.60M0.00-$4.94M$0.10N/A Do institutionals and insiders have more ownership in BIOA or CDXC? 15.4% of ChromaDex shares are owned by institutional investors. 20.8% of BioAge Labs shares are owned by company insiders. Comparatively, 9.6% of ChromaDex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryChromaDex beats BioAge Labs on 10 of the 12 factors compared between the two stocks. Get BioAge Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIOA vs. The Competition Export to ExcelMetricBioAge LabsPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$153.44M$784.81M$2.21B$9.02BDividend YieldN/A4.84%2.67%4.05%P/E RatioN/A1.3022.6520.08Price / SalesN/A230.4997.8693.26Price / CashN/A23.4414.1428.59Price / Book0.466.23116.845.55Net Income-$71.11M-$27.94M-$166.90M$248.49M7 Day Performance1.21%2.40%0.98%4.87%1 Month PerformanceN/A8.93%1.90%6.63%1 Year PerformanceN/A8.65%20.13%20.38% BioAge Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIOABioAge LabsN/A$4.18-2.3%N/AN/A$153.44MN/A0.00N/ACDXCChromaDex3.1826 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120DNTHDianthus Therapeutics1.8292 of 5 stars$19.12+4.0%$53.00+177.3%-27.6%$606.22M$6.52M-6.6480MENSJyong BiotechN/A$7.94-17.5%N/AN/A$603.66MN/A0.0031High Trading VolumeMGTXMeiraGTx4.5092 of 5 stars$7.51+8.5%$24.00+219.8%+92.5%$603.54M$34.51M-3.23300Analyst UpgradeUPBUpstream BioN/A$11.20+0.6%$56.50+404.5%N/A$602.49M$2.37M0.0038XNCRXencor3.9942 of 5 stars$8.41+1.3%$28.00+233.1%-56.4%$599.26M$127.23M-2.75280EOLSEvolus3.6664 of 5 stars$9.27+0.7%$23.75+156.2%-16.4%$597.69M$275.46M-10.42170Positive NewsKALVKalVista Pharmaceuticals4.2319 of 5 stars$11.90+1.0%$24.83+108.7%+27.7%$595.60MN/A-3.20100News CoverageUpcoming EarningsAnalyst ForecastGap UpIOVAIovance Biotherapeutics4.7408 of 5 stars$1.75+0.2%$12.22+596.8%-76.6%$584.39M$212.68M-1.41500Trending NewsARVNArvinas3.2385 of 5 stars$7.89-0.1%$20.29+157.1%-68.6%$580.28M$426.90M-11.96420 Related Companies and Tools Related Companies CDXC Alternatives DNTH Alternatives MENS Alternatives MGTX Alternatives UPB Alternatives XNCR Alternatives EOLS Alternatives KALV Alternatives IOVA Alternatives ARVN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIOA) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAge Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAge Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIOA Stock Alerts